Erektil disfonksiyon ve Peyronie hastalığında ESWT başarısı

Erektil Disfonksiyon (ED) tedavisine, ED’ye neden olan diyabet, kardi- yovasküler nedenler, ilaç kullanımı gibi düzeltilebilir faktörlerin ortadan kaldırılması ve yaşam tarzı değişiklikleri ile başlanmalıdır. Şu anda ED tedavisinde çoğunlukla fosfodiesteraz tip 5 inhibitörleri kullanılmakta - dır ve bazı hastalarda tedavi başarısız olmaktadır. Peyronie hastalığına bağlı ED tedavisinde kullanılan cerrahi ve cerrahi olmayan yöntemler- den tatmin edici sonuçlar elde etmek genellikle zordur. Son araştırmalar ekstrakorporeal şok dalga tedavisinin neoanjiyogenezi indüklediği ve penil hemodinamiyi olumlu etkilediği belirtilmektedir. Bu derlemede, erektil disfonksiyon ve Peyronie hastalığının tedavisi için ekstrakorpo - real şok dalga tedavisinin klinik etkinliğine dair kanıtlar yer almaktadır.

ESWT success in erectile dysfunction and Peyronie’s disease

Treatment of Erectile Dysfunction (ED) should be started with the elimination of correctable factors such as diabetes, cardiovascular causes, and drug use that cause ED, and lifestyle changes. Currently ED treatment mostly depends on phosphodiesterase type 5 inhibitors, which fail for some ED patients. Surgical and nonsurgical treatments in Peyronie’s disease related ED are frequently difficult to achieve satisfactory results. Recent studies indicate that extracorporeal shock wave therapy induces neoangiogenesis and positively affects on penile hemodynamics. In this review the evidence of clinical efficacy of extracorporeal shock wave therapy for the treatment of erectile dysfunction and Peyronie’s disease.

___

  • 1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83–90. [CrossRef]
  • 2. Salonia A, Bettocchi C, Capogrosso P, Carvalho J, Corona G, Hatzichristodoulou G, et al. European Association of Urology Guidelines on Sexual and Reproductive Health; 2022 Update. https://d56bochluxqnz.cloudfront.net/documents/ full-guideline/EAU-Guidelines-on-Sexual-and-Reproductive Health-2023.pdf
  • 3. Chaussy C, Schmiedt E, Jocham D, Brendel W, Forssmann B, Walther V. First clinical experience with extracorporeally induced destruction of kidney stones by shock waves. J Urol. 1982;127:417– 20. [CrossRef]
  • 4. Porst H. Review of the current status of low intensity extracorporeal shockwave therapy (Li-ESWT) in erectile dysfunction (ED), Peyronie’s disease (PD), and sexual rehabilitation after radical prostatectomy with special focus on technical aspects of the different marketed ESWT devices including personal experiences in 350 patients. Sex Med Rev. 2021;9:93–122. [CrossRef]
  • 5. Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010;58:243–8. [CrossRef]
  • 6. Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low-intensity extracorporeal shockwave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol. 2012;187:1769–75. [CrossRef]
  • 7. Capogrosso P, Di Mauro M, Fode M, Lowenstein L, Reisman Y, Dehò F, et al.; European Association of Urology Young Academic Urologists (EAU-YAU) Men’s Health Working Group. Low intensity extracorporeal shockwave therapy among urologist practitioners: how the opinion of urologists changed between 2016 and 2019. Int J Impot Res. 2020;33:839–43. [CrossRef]
  • 8. Sokolakis I, Dimitriadis F, Teo P, Hatzichristodoulou G, Hatzichristou D, Giuliano F. The basic science behind low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic scoping review of pre-clinical studies. J Sex Med. 2019;16:168–94. [CrossRef]
  • 9. Peng D, Tan Y, Reed-Maldonado AB, Lin G, Lue TF. Molecular mechanism of action of low-intensity extracorporeal shockwave therapy for regenerating penile and peripheral nerves. Turk J Urol. 2022;48:354–62. [CrossRef]
  • 10. Pai R, Ory J, Delgado C, Ramasamy R. Energy-based therapies for erectile dysfunction: current and future directions. Urol Clin North Am. 2021;48:603–10. [CrossRef]
  • 11. Wang HS, Ruan Y, Banie L, Cui K, Kang N, Peng D, et al. Delayed low-intensity extracorporeal shock wave therapy ameliorates impaired penile hemodynamics in rats subjected to pelvic neurovascular injury. J Sex Med. 2019;16:17–26. [CrossRef]
  • 12. Sokolakis I, Dimitriadis F, Psalla D, Karakiulakis G, Kalyvianakis D, Hatzichristou D. Effects of low-intensity shock wave therapy (LiST) on the erectile tissue of naturally aged rats. Int J Impot Res. 2019;31:162–9. [CrossRef]
  • 13. Zhu GQ, Jeon SH, Bae WJ, Choi SW, Jeong HC, Kim KS, et al. Efficient promotion of autophagy and angiogenesis using mesenchymal stem cell therapy enhanced by the low-energy shock waves in the treatment of erectile dysfunction. Stem Cells Int. 2018;2018:1302672. [CrossRef]
  • 14. Lin G, Reed-Maldonado AB, Wang B, Lee YC, Zhou J, Lu Z, et al. In situ activation of penile progenitor cells with low-intensity extracorporeal shockwave therapy. J Sex Med. 2017;14:493–501. [CrossRef]
  • 15. Wang H-J, Cheng J-H, Chuang Y-C. Potential applications of low energy shock waves in functional urology. Int J Urol. 2017;24:573– 81. [CrossRef]
  • 16. Li H, Matheu MP, Sun F, Wang L, Sanford MT, Ning H, et al. Low-energy shock wave therapy ameliorates erectile dysfunction in a pelvic neurovascular injuries rat model. J Sex Med. 2016;13:22– 32. [CrossRef]
  • 17. Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol. 2017;71:223–33. [CrossRef]
  • 18. Dong L, Chang D, Zhang X, Li J, Yang F, Tan K, et al. Effect of low-intensity extracorporeal shock wave on the treatment of erectile dysfunction: a systematic review and meta-analysis. Am J Mens Health. 2019;13:1557988319846749. [CrossRef]
  • 19. Ortac M, Özmez A, Cilesiz NC, Demirelli E, Kadıoğlu A. The impact of extracorporeal shock wave therapy for the treatment of young patients with vasculogenic mild erectile dysfunction: A prospective randomized single-blind, sham controlled study. Andrology. 2021;9:1571–8. [CrossRef]
  • 20. Brunckhorst O, Wells L, Teeling F, Muir G, Muneer A, Ahmed K. A systematic review of the long-term efficacy of low-intensity shockwave therapy for vasculogenic erectile dysfunction. Int Urol Nephrol. 2019;51:773–81. [CrossRef]
  • 21. Mason MM, Pai RK, Masterson JM, Lokeshwar SD, Chu KY, Ramasamy R. Low-intensity extracorporeal shockwave therapy for diabetic men with erectile dysfunction: a systematic scoping review. Andrology. 2023;11:270–81. [CrossRef]
  • 22. Scroppo FI, Pezzoni F, Gaeta F, Pastore LA, Malfatto M, Cai T, et al. Li-Eswt improves hemodynamic parameters thus suggesting neoangiogenesis in patients with vascular erectile dysfunction. Int J Impot Res. 2022;34:237–42. [CrossRef]
  • 23. Gruenwald I, Kitrey ND, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy in vascular disease and erectile dysfunction: theory and outcomes. Sex Med Rev. 2013;1:83–90. [CrossRef]
  • 24. Kalyvianakis D, Hatzichristou D. Low-intensity shockwave therapy improves hemodynamic parameters in patients with vasculogenic erectile dysfunction: a triplex ultrasonography-based sham-controlled trial. J Sex Med. 2017;14:891–7. [CrossRef]
  • 25. Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy –a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med. 2012;9:259–64. [CrossRef]
  • 26. Kitrey ND, Gruenwald I, Appel B, Shechter A, Massarwa O, Vardi Y. Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol. 2016;195:1550–5. [CrossRef]
  • 27. Schoofs E, Fode M, Capogrosso P, Albersen M; European Association of Urology Young Academic Urologists (EAU - YAU) Men’s Health Group. Current guideline recommendations and analysis of evidence quality on low-intensity shockwave therapy for erectile dysfunction. Int J Impot Res. 2019;31:209–17. [CrossRef ]
  • 28. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61. [CrossRef]
  • 29. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia. 2004;47:1914–23. [CrossRef]
  • 30. Assaly-Kaddoum R, Giuliano F, Laurin M, Gorny D, Kergoat M, Bernabé J, et al. Low intensity extracorporeal shock wave therapy improves erectile function in a model of type II diabetes independently of NO/cGMP pathway. J Urol. 2016;196:950–6. [CrossRef]
  • 31. Spivak L, Shultz T, Appel B, Verze P, Yagudaev D, Vinarov A. Low intensity extracorporeal shockwave therapy for erectile dysfunction in diabetic patients. Sex Med Rev. 2021;9:619–27. [CrossRef]
  • 32. Verze P, Capece M, Creta M, La Rocca R, Persico F, Spirito L, et al. Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. Asian J Androl. 2020;22:379–82. [CrossRef]
  • 33. Ergün M, Akyüz O. Is Li-ESWT effective in diabetic patients with severe erectile dysfunction? Asian J Androl. 2022;24:521–4. [CrossRef]
  • 34. Frey A, Sønksen J, Fode M. Low-intensity extracorporeal shockwave therapy in the treatment of postprostatectomy erectile dysfunction: a pilot study. Scand J Urol. 2016;50:123–7. [CrossRef]
  • 35. Zewin TS, El-Assmy A, Harraz AM, Bazeed M, Shokeir AA, Sheir K, Mosbah A. Efficacy and safety of low-intensity shock wave therapy in penile rehabilitation post nerve-sparing radical cystoprostatectomy: a randomized controlled trial. Int Urol Nephrol. 2018;50:2007–14. [CrossRef]
  • 36. Baccaglini W, Pazeto CL, Corrêa Barros EA, Timóteo F, Monteiro L, Saad Rached RY, et al. The role of the low-intensity extracorporeal shockwave therapy on penile rehabilitation after radical prostatectomy: a randomized clinical trial. J Sex Med. 2020;17:688–94. [CrossRef]
  • 37. Sighinolfi MC, Eissa A, Bellorofonte C, Mofferdin A, Eldeeb M, Assumma S, et al. Low-intensity extracorporeal shockwave therapy for the management of postprostatectomy erectile dysfunction: a systematic review of the literature. Eur Urol Open Sci. 2022;43:45– 53. [CrossRef]
  • 38. Yamaçake KG, Carneiro F, Cury J, Lourenço R, Françolin PC, Piovesan AC, et al. Low-intensity shockwave therapy for erectile dysfunction in kidney transplant recipients. A prospective, randomized, double blinded, sham-controlled study with evaluation by penile Doppler ultrasonography. Int J Impot Res. 2019;31:195–203. [CrossRef]
  • 39. Cocci A, Fassio G, Migliorini F, Cito G, Antonelli A, Verrienti P, et al. Low-intensity extracorporeal shock wave therapy (Li-ESWT) for priapism-induced erectile dysfunction in young patients: the first case series. Int J Impot Res. 2022;34:277–9. [CrossRef]
  • 40. Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200:633–41. [CrossRef]
  • 41. Chung E, Lee J, Liu CC, Taniguchi H, Zhou HL, Park HJ. Clinical practice guideline recommendation on the use of low intensity extracorporeal shock wave therapy and low intensity pulsed ultrasound shock wave therapy to treat erectile dysfunction: the Asia-Pacific Society for Sexual Medicine position statement. World J of Mens Health. 2021;39:1–8. [CrossRef]
  • 42. Domes T, Najafabadi BT, Roberts M, Campbell J, Flannigan R, Bach P, et al. Canadian Urological Association guideline: erectile dysfunction. Can Urol Assoc J. 2021;15:310–22. [CrossRef]
  • 43. Capogrosso P, Frey A, Jensen CFS, Rastrelli G, Russo GI, Torremade J, et al. Low-intensity shock wave therapy in sexual medicine-clinical recommendations from the European Society of Sexual Medicine (ESSM). J Sex Med. 2019;16:1490–505. [CrossRef]
  • 44. Liu JL, Chu KY, Gabrielson AT, Wang R, Trost L, Broderick G, et al. Restorative therapies for erectile dysfunction: position statement from the Sexual Medicine Society of North America (SMSNA). Sex Med. 2021;9:100343. [CrossRef]
  • 45. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503. [CrossRef]
  • 46. Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol. 1997;158:1388–90. [CrossRef]
  • 47. Devine CJ Jr, Somers KD, Jordan GH, Schlossberg SM. Proposal: trauma as a cause of Peyronie’s lesion. J Urol. 1997;157:285–90. [CrossRef]
  • 48. Levine L. Peyronie’s disease and erectile dysfunction: current understanding and future direction. Indian J Urol. 2006;22:246– 50. [CrossRef]
  • 49. Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, et al.; European Association of Urology. EAU guidelines on penile curvature. Eur Urol. 2012;62:543–52. [CrossRef]
  • 50. Gao L, Qian S, Tang Z, Li J, Yuan J. A meta-analysis of extracorporeal shock wave therapy for Peyronie’s disease. Int J Impot Res. 2016;28:161–6. [CrossRef]
  • 51. Fojecki GL, Tiessen S, Osther PJ. Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie’s disease, erectile dysfunction and chronic pelvic pain. World J Urol. 2017;35:1–9. [CrossRef]
  • 52. Krieger JR, Rizk PJ, Kohn TP, Pastuszak A. Shockwave therapy in the treatment of Peyronie’s disease. Sex Med Rev. 2019;7:499–507. [CrossRef]
  • 53. Bakr AM, El-Sakka AI. Extracorporeal shockwave therapy in Peyronie’s disease: systematic review and meta-analysis. J Sex Med. 2021;18:1705–14. [CrossRef]
  • 54. Sokolakis I, Pyrgidis N, Lahme S, Hatzichristodoulou G. Low intensity shockwave therapy in Peyronie’s disease: long-term results from a prospective, randomized, sham-controlled trial. Int J Impot Res. 2022;34:487–94. [CrossRef]
  • 55. Abdessater M, Akakpo W, Kanbar A, Parra J, Seisen T, Chartier Kastler E, et al. Low-intensity extracorporeal shock wave therapy for Peyronie’s disease: a single-center experience. Asian J Androl. 2022;24:45–9. [CrossRef]
  • 56. Bella AJ, Lee JC, Grober ED, Carrier S, Benard F, Brock GB. 2018 Canadian Urological Association guideline for Peyronie’s disease and congenital penile curvature. Can Urol Assoc J. 2018;12:E197-E209.